Verition Fund Management’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,301
Closed -$447K 2316
2025
Q4
$447K Sell
11,301
-6,451
-36% -$236K ﹤0.01% 2744
2025
Q3
$626K Buy
17,752
+9,924
+127% +$342K ﹤0.01% 2890
2025
Q2
$257K Sell
7,828
-442,058
-98% -$14.4M ﹤0.01% 3270
2025
Q1
$14.5M Buy
449,886
+427,165
+1,880% +$15.9M 0.07% 318
2024
Q4
$694K Buy
+22,721
New +$731K ﹤0.01% 2272
2023
Q3
Sell
-7,328
Closed -$362K 2344
2023
Q2
$362K Buy
+7,328
New +$338K ﹤0.01% 1424
2022
Q1
Sell
-29,361
Closed -$2.04M 2710
2021
Q4
$2.04M Buy
+29,361
New +$2.13M 0.01% 872

Other funds holding ATRC

Verition Fund Management's ATRC Position: Q1 2026 in Review

Verition Fund Management sold out of AtriCure (ATRC) in Q1 2026, closing a stake of 11,301 shares — an estimated $447K sold.

Verition Fund Management first reported a position in ATRC in Q4 2021 and held it in 7 quarters. The position peaked at $14.5M in Q1 2025. 224 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.

  • Verition Fund Management reported no remaining AtriCure position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 11,301 AtriCure shares in Q1 2026, an estimated $447K.
  • Verition Fund Management first reported a position in AtriCure in Q4 2021 and held it in 7 quarters.
  • Verition Fund Management's AtriCure position peaked at $14.5M in Q1 2025.
  • 224 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.